Session III
Abdominal Aortic Aneurysms Session : genetics, pathophysiology and clinical studies
Part one
Moderators : G. Cockerill, G. Tromp
8h30Abdominal aortic aneurysms are deep, deadly and genetic.
H. Kuivaniemi
8h50Evidence for autoimmunity in the AAA.
D. Tilson
9h10Aneurysm or occlusive disease-factors determining the clinical course of atherosclerosis of the infrarenal aorta.
BT. Baxter
9h30Role of the inflammatory cells during the development of the aortic aneurysms.
RW. Thompson
9h50The role of the mural thrombus during the development and rupture of AAA.
J. Swedenborg
10h10 – 10h30 Discussion
10h30 – 11h00 Coffee Break
Part two
Moderators : J. Lindholt, H. Massin
11h00
Natural history of unoperated AAA.
F. Lederle
11h20Benefits of screening for abdominal aortic aneurysms concerning ruptures, operations and mortality - a metaanalysis.
J. Lindholt
11h40From phenotype to genotype ?
J. Powell
12h00 – 12h20 Discussion
12h20 – 14h00 Lunch
14h00 Serological biomarkers of progression and rupture of abdominal aortic aneurysms.
S. Urbonavicius
14h20 Functional imaging of AAA.
N. Sakalihasan
14h40Treatment of AAA in high-risk patients : Open repair or EVAR ?
F. Lederle
15h00Late results of endovascular aneurysm repair versus open aneurysm repair.
J. Blankensteijn
15h20 The place of the endovascular treatment of AAA today: a Scandinavian point of view.
L. Lonn
15h40 – 16h05 Discussion
16h05 – 16h30 Coffee Break
Session IV
New treatment options for aortic aneurysms
Moderators : E. Steinmetz, B.T. Baxter
16h30Medical treatment of the Marfan disease.
G. Jondeau
16h50Pharmacological therapy of AAA (in animals).
K. Yoshimura
17h10Endovascular cell therapy of AAA.
E. Allaire
17h30Could abdominal aortic aneurysms be treated medically (clinical trials) ?
BT. Baxter
17h50 – 18h10 Discussion
18h10Closing remarks
J. Powell & H. Kuivaniemi
↑ Top